Targeting B cells in Graves' disease.
Wang
Su He
SH
Department of Internal Medicine, Medical School, University of Michigan, 1150 West Medical Center Drive, 1520/MSRBI, Ann Arbor, 48109, USA.
Baker
James R
JR
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000494:pharmacology; D015551:Autoimmunity / Q000502:physiology; D053265:B-Cell Activation Factor Receptor; D001402:B-Lymphocytes / Q000276:immunology*; D006111:Graves Disease / Q000276:immunology*; D006801:Humans; D008565:Membrane Proteins / Q000378:metabolism / Q000502:physiology; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism; D000069283:Rituximab; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D053265:B-Cell Activation Factor Receptor; D008565:Membrane Proteins; D018124:Receptors, Tumor Necrosis Factor; C435926:TNFRSF13C protein, human; C114631:TNFSF13 protein, human; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab